These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: An overview of the results of clinical trials with alendronate, a promising treatment of osteoporosis in postmenopausal women.
    Author: Hirsch LJ, Pryor-Tillotson S.
    Journal: Ann Ital Med Int; 1995 Oct; 10 Suppl():22S-28S. PubMed ID: 8562261.
    Abstract:
    The purpose of this overview is to provide a summary of recent data on the clinical safety and efficacy of alendronate sodium, an amino-bisphosphonate that is a potent and specific inhibitor of osteoclast mediated bone resorption, in the treatment of osteoporosis in postmenopausal women. Published data are available from two randomized, placebo-controlled, double-blind clinical trials of 2-year duration in over 470 patients with postmenopausal osteoporosis. The women studied were 4 to 5 years postmenopause, ages 42 to 76, with osteoporosis defined on the basis of low spine bone mineral density (BMD). Percent change in spine BMD was the primary endpoint; hip and total body BMD were secondary outcomes. In the Dose Ranging Study, alendronate 5 and 10 mg/day for 2 years significantly increased lumbar spine BMD by approximately 7.2%, which did not differ from patients receiving higher doses. Total hip BMD increased by 3.6 and 5.3%, respectively, with the 5 and 10 mg doses; 10 mg was significantly more effective than 5 mg. Placebo patients lost 1.2-1.4% BMD at these sites. Total body BMD also significantly increased with alendronate. In the Calcitonin Comparison Study, alendronate 10 and 20 mg/day for 2 years significantly increased spine and hip BMD; 100 IU of intranasal salmon calcitonin did not increase BMD at any site, and did not differ from placebo. Alendronate reduced bone turnover to a new steady state, as assessed by biochemical markers and was well tolerated. Preliminary reports indicate that alendronate progressively increases spine, hip, and total body bone mass for 3 years, with associated significant reductions in vertebral fractures, stature loss, and non-vertebral fractures.(ABSTRACT TRUNCATED AT 250 WORDS)
    [Abstract] [Full Text] [Related] [New Search]